Clinical trialEPhase 1Terminated
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma
- Outcome
- Stopped earlyFrom preliminary imaging data, the study was stopped due to futility. (Efficacy or futility)
- Phase
- EPhase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- November 2013
- Expected end
- January 2016
- Enrollment
- 3 participants
- Sites
- 1
- Primary outcomes
- Ability of PTP-01 to detect pancreatic ductal adenocarcinoma
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 March 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers at the University of Virginia have identified a biomarker for pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other, non-cancerous conditions involving the pancreas. These researchers have also developed PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer cells in humans.